Insilico Medicine, a Hong Kong-based firm that uses artificial intelligence (AI) for drug discovery and ageing research, announced on Tuesday that it has raked in $255 million in a Series C round of financing led by US private equity (PE) giant Warburg Pincus.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
